Listed

Tempest Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2018

Filed with the SEC on Nov 9, 2018 and accepted by EDGAR at Nov 9, 2018, 17:24 ET.

Share

Management's discussion and analysis

As filed, 27,746 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Without limiting the foregoing, the words “may,” “shall,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “target,” “goal”, “seek”, “likely,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth in this Item 2 — “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2017 and in Part II, Item 1A “Risk Factors” of this Quarterly Report.

Overview

OvaScience, Inc., incorporated on April 5, 2011 as a Delaware corporation, is a company focused on the discovery and development of new treatment options for women and families struggling with infertility. As used in this Quarterly Report, the terms “OvaScience,” “the Company,” “we,” “us,” and “our” refer to the business of OvaScience, Inc. and its wholly owned subsidiaries. To date OvaScience has been leveraging the breakthrough discovery of egg precursor, or EggPCSM, cells to transform the treatment landscape for women's fertility. OvaScience's operations to date have been limited to organizing and staffing the company, business planning, raising capital, acquiring and developing our technology, identifying potential fertility treatments, developing the OvaPrimeSM treatment, the OvaTureSM treatment and the AUGMENTSM treatment, introducing AUGMENT in select international in vitro fertilization ("IVF") clinics and determining the regulatory and development path for OvaScience's fertility treatments. OvaScience has generated limited revenues to date, and does not anticipate significant revenues in the near term. In June 2017, OvaScience announced that it would continue to focus on advancing OvaPrime in clinical development and OvaTure in preclinical development and would discontinue ongoing efforts related to the AUGMENT treatment outside of North America. To better align its organization with these strategic priorities, OvaScience restructured its workforce and reduced its workforce by approximately 50%. On January 3, 2018, OvaScience announced a further restructuring of its organization and a workforce reduction of approximately 50%. On May 3, 2018, OvaScience announced that its Board of Directors had approved a corporate restructuring plan furthering its on-going efforts to effectively align its resources. On August 9, 2018, OvaScience announced that it had entered into a definitive agreement with Millendo Therapeutics, Inc. ("Millendo") under which Millendo will merge with OvaScience in an all-stock transaction. A wholly owned subsidiary of OvaScience will merge with and into Millendo, with Millendo surviving as a wholly owned subsidiary of OvaScience (the "Merger"). OvaScience and Millendo believe that the Merger will result in a specialty biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The transaction has been approved by the Boards of Directors of both companies. The Merger is expected to close in the fourth quarter of 2018, subject to the approval of OvaScience shareholders at a special shareholder meeting to be held on December 4, 2018, as well as other customary conditions.

17

Critical Accounting Policies and Significant Judgments and Estimates

The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments, estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We evaluate our estimates, on an ongoing basis, including those related to accrued expenses and assumptions in the valuation of stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances. Actual results could differ from those estimates.

Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2017 for a discussion of our critical accounting policies and estimates.

There were no significant changes to our critical accounting policies and estimates in the nine months ended September 30, 2018.

Results of Operations

The following table summarizes our results of operations for the three and nine months ended September 30, 2018 and 2017, together with the changes from period to period (in thousands of dollars except for percentages):

Three Months Ended, September 30, 2018 2017 2018/ 2017 Comparison Increase / (Decrease) $% Nine Months Ended September 30, 2018 2017 2018 / 2017 Comparison Increase / (Decrease) $%
Revenues $55 $56 $(1) (2)% $203 $204 $(1) —%
Costs of revenues 44 29 15 52% 210 572 (362) (63)%
Research and development expenses 1,680 4,016 (2,336) (58)% 6,695 14,777 (8,082) (55)%
Selling, general and administrative expenses 4,176 5,056 (880) (17)% 11,045 22,935 (11,890) (52)%
Restructuring 53 361 (308) (85)% 3,637 3,842 (205) (5)%
Interest income, net 228 193 35 18% 643 560 83 15%
Other income (expense), net (7) (3) 4 133% (5) (37) (32) (86)%
Loss from equity method investment 2 140 (138) (99)% 6 1,015 (1,009) (99)%
Income tax expense — 11 (11) (100)% — 33 (33) (100)%
Net loss $5,679 $9,367 $(3,688) (39)% $20,752 $42,447 $(21,695) (51)%

Revenues

Revenues for the three and nine months ended September 30, 2018 were $55.0 thousand and $203.0 thousand, respectively as compared to $56.0 thousand and $204.0 thousand for the three and nine months ended September 30, 2017, respectively. We do not anticipate significant revenue from our programs in the near term.

18

Cost of Revenues

Costs of revenues for the three and nine months ended September 30, 2018 were $44.0 thousand and $0.2 million, respectively, compared to $29.0 thousand and $0.6 million for the three and nine months ended September 30, 2017, respectively. The decrease in costs of revenues for the nine months ended September 30, 2018 is attributable to the decrease in the number of biopsies performed primarily as a result of our shift in corporate priorities related to AUGMENT resulting from our restructuring activities and the related pricing programs offered, as well as a decrease in compensation costs resulting from our restructuring activities. Our costs of revenues include the cost of processing patient tissue that corresponds to treatment revenues for the reporting period. Given our shift in corporate priorities and focus on research and development, we expect cost of revenues to continue to decrease in the future.

Research and Development Expense

The $2.3 million, or 58%, decrease in our research and development expense for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017, from $4.0 million to $1.7 million was primarily attributable to:

  • a $1.3 million decrease in employee compensation, including stock-based compensation, as a result of our corporate restructuring activities;
  • a $0.1 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives; and
  • a $0.9 million decrease in marketing, professional and commercial related costs primarily attributable to our shift in corporate strategy to focus on research and development activities.

The $8.1 million, or 55%, decrease in our research and development expense for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017, from $14.8 million to $6.7 million was primarily attributable to:

  • a $4.9 million decrease in employee compensation, including stock-based compensation, as a result of our corporate restructuring activities;
  • a $1.7 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives; and
  • a $1.5 million decrease in research and consulting costs primarily attributable to the decrease in our headcount and our corporate restructuring activities.

Our research and development expense would increase if our programs were to successfully advance towards commercialization. We do not believe that our historical costs are indicative of the future costs associated with these programs nor do they represent what any other future treatment program we initiate may cost. Due to the variability in the length of time and scope of activities necessary to develop a fertility treatment and uncertainties related to cost estimates and our ability to commercialize and/or obtain marketing approval for our fertility treatments, accurate and meaningful estimates of the total costs required to bring our fertility treatments to market are not available.

Additionally, because of the risks inherent in drug discovery and development, we cannot reasonably estimate or know:

  • the nature, timing and estimated costs of the efforts necessary to complete the development of our treatments;
  • the anticipated completion dates of our treatment development efforts, if any; or
  • the period in which material net cash in-flows are expected to commence, if at all, from our current treatments and any potential future treatments.

Selling, General and Administrative Expense

The $0.9 million, or 17%, decrease in selling, general and administrative expense for the three months ended September 30, 2018 as compared to the three months ended September 30, 2017, from $5.1 million to $4.2 million was primarily attributable to:

  • a $1.1 million decrease in employee compensation, including stock-based compensation, a result of our corporate restructuring activities;

19

  • a $0.3 million decrease in marketing and commercial related activities primarily attributable to our shift in corporate strategy to focus on research and development activities; and
  • a $0.5 million increase in in legal and professional costs primarily attributable to the settlement of ongoing litigation.

The $11.9 million, or 52%, decrease in selling, general and administrative expense for the nine months ended September 30, 2018 as compared to the nine months ended September 30, 2017, from $22.9 million to $11.0 million was primarily attributable to:

  • a $8.7 million decrease in employee compensation, including stock-based compensation, a result of our corporate restructuring activities;
  • a $1.2 million decrease in marketing and commercial related activities primarily attributable to our shift in corporate strategy to focus on research and development activities; and
  • a $2.0 million decrease in travel, facilities and other costs primarily attributable to the decrease in our headcount as result of our corporate restructuring initiatives.

We expect selling, general and administrative expense to continue to decrease as a result of the corporate restructuring announcements in December 2016, June 2017, January 2018 and May 2018. We do not believe that our historical costs of supporting AUGMENT represent what any other future commercial treatment program we initiate may cost to support and do not anticipate substantial costs associated with supporting AUGMENT.

Restructuring Expense

Restructuring expenses were $0.0 million and $3.6 million for the three and nine months ended September 30, 2018, respectively. During the nine months ended September 30, 2018, we recognized restructuring charges of $3.6 million, primarily comprised of $1.4 million of one-time termination benefits attributable to our January 2018 and May 2018 restructuring activities and $2.2 million of asset impairment charges attributable to our May 2018 restructuring activities.

Restructuring expenses were $0.4 million and $3.8 million for the three and nine months ended September 30, 2017. For the three months ended September 30, 2017, we recognized restructuring charges of $0.4 million relating to one-time termination benefits. For the nine months ended September 30, 2017, we recognized restructuring charges of $3.8 million, including $2.7 million of one-time termination benefits, $0.3 million recorded of benefits under an ongoing benefit plan, $0.3 million of fixed asset impairment charges and $0.6 million of other restructuring related costs primarily consisting of legal fees.

Interest Income, Net

Interest income, net was $0.2 million for the three months ended September 30, 2018 and 2017, which for both periods was comprised of $0.2 million of interest income related to short-term investments.

Interest income, net was $0.6 million for the nine months ended September 30, 2018 and 2017, which for both periods was comprised of $0.6 million of interest income related to short-term investments.

Loss from Equity Method Investment

Loss from equity method investment from our OvaXon joint venture was de minimis for the three and nine months ended September 30, 2018. Loss from equity method investment from this joint venture was $0.1 million and $1.0 million for the three and nine months ended September 30, 2017.

Income Tax Expense

Income tax expense was immaterial for the three and nine months ended September 30, 2018 and September 30, 2017. Income tax expense primarily consists of taxes incurred in the state and foreign jurisdictions in which we operate.

20

Liquidity and Capital Resources

Sources of Liquidity

We have generated limited AUGMENT treatment revenue to date and do not anticipate any significant revenues in the near-term. We have relied on the proceeds from sales of equity securities to fund our operations. Our short-term investments primarily trade in liquid markets, and the average days to maturity of our portfolio as of September 30, 2018 are less than 12 months. Because our fertility treatments are in various stages of development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our fertility treatments, or whether or when we may achieve profitability.

Our significant capital resources are as follows (in thousands):

September 30, 2018 December 31, 2017
Cash, cash equivalents and short-term investments $46,350 $67,203
Working capital 45,105 60,977
Cash (used in) provided by: Nine Months Ended September 30, 2018 2017
Operating activities $(21,492) $(37,579)
Investing activities 37,706 18,774
Capital expenditures (included in investing activities above) — (112)
Financing activities — —

Cash Flows

Cash used in operating activities in both of the periods presented was primarily driven by our net loss. Cash flows used in operations can vary significantly due to various factors, including changes in the net loss and the timing of disbursements made for accounts payable and accruals.

Cash provided by investing activities for the nine months ended September 30, 2018 included $70.8 million of proceeds from maturities of short-term investments and $0.4 million of proceeds from the sale of property, plant and equipment, which were offset by purchases of $33.5 million of short-term investments.

Cash provided by investing activities for the nine months ended September 30, 2017 included purchases of $48.4 million of short-term investments and capital expenditures of $0.1 million, which were offset by $67.8 million of proceeds from maturities of short-term investments. Capital expenditures in the nine months ended September 30, 2017 primarily consisted of laboratory equipment.

Net cash provided by financing activities for both the nine months ended September 30, 2018 and September 30, 2017 was zero.

21

We will need substantial additional funds to support our planned operations. We expect that our existing cash, cash equivalents and short-term investments of $46.4 million at September 30, 2018 will enable us to fund our current operating plan for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our fertility treatments, and the extent to which we may enter into collaborations with third parties for development and commercialization of our fertility treatments, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our current treatments in development. Our future capital requirements will depend on many factors, including:

  • the costs associated with clinical studies and trials;
  • the costs involved in collaborating with our academic and commercial partners, and any contract research organizations;
  • preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
  • establishing collaborations and partnerships on favorable terms, if at all;
  • developing, acquiring or in-licensing other potential fertility treatments and technologies; and
  • the timing for completion of our transaction with Millendo.

Until such time, if ever, as we can generate sufficient revenues from our fertility treatments to become profitable, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. In addition, we may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or treatments or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our fertility treatment development or future commercialization efforts or grant rights to develop and market treatments that we would otherwise prefer to develop and market ourselves.

Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Contractual Obligations

There have been no material changes to our contractual obligations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2017.

22

Recent Accounting Pronouncements

In August 2018, the Financial Accounting Standards Board ("FASB") issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. This update is effective for annual and interim periods beginning after December 15, 2019 with early adoption permitted. We are currently assessing the impact ASU 2018-13 will have on our consolidated financial statements and footnote disclosures thereto.

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Non-employee Share-Based Payment Accounting. ASU 2018-07 is intended to reduce the cost and complexity and to improve financial reporting for non-employee share-based payments. The ASU expands the scope of Topic 718, Compensation-Stock Compensation (which currently only includes share-based payments to employees), to include share-based payments issued to non-employees for goods or services. Consequently, the accounting for share-based payments to non-employees and employees will be substantially aligned. This update is effective for annual and interim periods beginning after December 15, 2018 with early adoption permitted. Upon transition, entities will remeasure unsettled liability-classified awards and any unmeasured equity-classified awards for non-employees at fair value as of the adoption date. A cumulative-effect adjustment to retained earnings will be required as of the beginning of the fiscal year of adoption. We are currently assessing the impact ASU 2016-13 will have on our consolidated financial statements and footnote disclosures thereto.

In November 2016, the FASB issued ASU No. 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This update is effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years using a retrospective transition method to each period presented. The Company adopted this standard as of January 1, 2018 on a retrospective basis, which resulted in the recast of the prior reporting period in the statement of cash flows. For the nine months ended September 30, 2018 and 2017, $0.8 million and $0.8 million, respectively, of restricted cash is included in the total of cash and restricted cash balance at the end of period. A reconciliation of cash and restricted cash from our condensed consolidated statement of cash flows to the amounts reported within our condensed consolidated balance sheet is also included in a table below our condensed consolidated statement of cash flows.

In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments. ASU 2016-15 requires changes in the presentation of debt prepayment or debt extinguishment costs, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies and distributions received from equity method investees. This update is effective for annual and interim periods beginning after December 15, 2017 using a retrospective transition method to each period presented. We adopted this standard as of January 1, 2018 with no material impact on our consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments, which amends the impairment model by requiring entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments. This may result in the earlier recognition of allowances for losses. The guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. We are currently assessing the impact ASU 2016-13 will have on our consolidated financial statements and footnote disclosures thereto.

In February 2016, the FASB issued ASU No. 2016-02, Leases, which is intended to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, a lessee will be required to recognize assets and liabilities for both operating and financing leases with lease terms of more than 12 months. The amendment is effective for annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted. In July 2018, the FASB issued ASU 2018-11, Leases, to address two requirements of ASU 2016-02. ASU 2018-11 allows entities to recognize a cumulative-effect adjustment from the application of ASU 2016-02 to the opening balance of retained earnings in the period of adoption. In addition, ASU 2018-11 provides lessors with a practical expedient to not separate non-lease components from the associated lease component if certain conditions are met. We are currently assessing the impact ASU 2016-02 will have on our consolidated financial statements and footnote disclosures thereto.

ASU 2014-09, Revenue from Contracts with Customers, amends the guidance for accounting for revenue from contracts with customers. ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, Revenue Recognition, and creates a new Topic 606, Revenue from Contracts with Customers. This guidance was effective for the

23

Company on January 1, 2018. Two adoption methods are permitted: retrospectively to all prior reporting periods presented, with certain practical expedients permitted; or retrospectively with the cumulative effect of initially adopting the ASU 2014-09 recognized at the date of initial application. We adopted ASU 2014-09 effective January 1, 2018 and elected to adopt ASU 2014-09 using the modified retrospective approach and applied the standard only to contracts that had not yet been completed as of January 1, 2018. The impact under this methodology to our previously reported revenues is insignificant in the periods reported, and therefore the Company did not record a cumulative catch-up to deferred revenue and accumulated deficit upon adoption of the new standard on January 1, 2018.

Market risk

As filed, 993 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since a significant portion of our investments are in money market funds and corporate obligations. We do not enter into investments for trading or speculative purposes. We maintain our cash, cash equivalents and short-term investments with a high quality, accredited financial institution. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase.

A hypothetical 100 basis point increase in interest rates would result in an approximately $0.1 million and $0.1 million decrease in the fair value of our investments as of September 30, 2018 and December 31, 2017, respectively. We have the ability to hold our fixed income investments until maturity and, therefore, we do not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

Controls and procedures

As filed, 1,952 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures. Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2018, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Controls. No change in our internal control over financial reporting occurred during the fiscal quarter ended September 30, 2018 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 4,054 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this report, you should carefully consider the risk factors discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2017. With the exception of the risk factors below, there here have been no material changes in or additions to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2017 and our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2018 and June 30, 2018.

We currently do not meet the continued listing standards of The Nasdaq Capital Market, which require a minimum closing bid price of $1.00 per share. Our failure to meet Nasdaq’s continued listing standards could result in the delisting of our common stock, negatively impact the price of our common stock and negatively impact our ability to raise additional capital.

Our common stock is listed on The Nasdaq Capital Market. Nasdaq provides various continued listing requirements that a company must meet in order for its stock to continue trading on The Nasdaq Capital Market. Among these requirements is the requirement that the Company’s stock trades at a minimum closing bid price of $1.00 per share. Listing Rule 5810(c)(3)

26

(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Our common stock has recently and consistently traded below $1.00 per share, including closing bid prices below $1.00 per share.

On April 27, 2018, we received a deficiency letter from Nasdaq, which indicated that the Company was not in compliance with the minimum bid price requirement set forth in Nasdaq rules for continued listing on The Nasdaq Global Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we were granted a grace period of 180 calendar days, or until October 24, 2018, to regain compliance with the minimum bid price requirement. During the compliance period, our common stock continued to be listed and traded on The Nasdaq Global Market. Because we were unable to regain compliance with the minimum bid price requirement during the compliance period, we submitted an application to transfer the listing of our common stock to The Nasdaq Capital Market, which, according to Nasdaq listing rules, affords us an additional 180-day compliance period to comply with the minimum bid price requirement. The transfer application also required us to submit a letter stating our intention to effect a reverse stock split during the second compliance period, which we have done. The application to transfer the listing of our common stock was granted on October 29, 2018, effective October 31, 2018. If we fail to regain compliance with the minimum bid price requirement during the second compliance period, our common stock could be subject to delisting. Additionally, if the Company fails to comply with any other continued listing standards of Nasdaq, our common stock will also be subject to delisting. There can be no assurance that we will be able to regain compliance with the minimum bid price requirement or will otherwise be in compliance with other Nasdaq listing criteria.

In the event that our common stock is delisted from The Nasdaq Capital Market, our common stock would be subject to rules that impose additional sales practice requirements on broker-dealers who sell our securities. The additional burdens imposed upon broker-dealers by these requirements could discourage broker-dealers from effecting transactions in our common stock. This would significantly and negatively affect the ability of investors to trade our securities and would significantly and negatively affect the value and liquidity of our common stock. These factors could contribute to lower prices and larger spreads in the bid and ask prices for our common stock. Delisting would prevent us from satisfying a closing condition for the proposed Merger, and, in such event, Millendo may elect not to consummate the proposed Merger.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-07-01 to 2018-09-30$55.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2018-01-01 to 2018-09-30$203.0kus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2018-07-01 to 2018-09-30$44.0kus-gaap:CostOfRevenue
Cost of revenue9 months2018-01-01 to 2018-09-30$210.0kus-gaap:CostOfRevenue
Research and development3 months2018-07-01 to 2018-09-30$1.7mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$6.7mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-07-01 to 2018-09-30$4.2mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2018-01-01 to 2018-09-30$11.0mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-07-01 to 2018-09-30−$5.9mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$21.4mus-gaap:OperatingIncomeLoss
Income tax3 months2018-07-01 to 2018-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax9 months2018-01-01 to 2018-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2018-07-01 to 2018-09-30−$5.7mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$20.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$0.16us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$0.58us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-01-01 to 2018-09-30−$21.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$0us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-30$31.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$49.0mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$49.2mus-gaap:Assets
Current liabilitiesAt period end2018-09-30$3.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$4.3mus-gaap:Liabilities
Shareholders' equityAt period end2018-09-30$44.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001544227-18-000009. Last ingested by Listed: Nov 15, 2026, 00:20 ET. Listed shows no prices and gives no investment advice.